Growth Hormone Resistance of Beta-cells

Growth Hormone Resistance of Beta-cells in People With Impaired Fasting Glucose vs Impaired Glucose Tolerance

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07581860

Acronym

GHRB-C

Enrollment

Registered

2026-05-12

Start date

2026-08-01

Completion date

2030-09-01

Last updated

2026-08-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy, Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (Prediabetes), Obesity & Overweight

Brief summary

The purpose of the research study is to better understand how beta-cells (cells in the pancreas that make insulin and help regulate blood sugar) respond to growth hormone in people with impaired fasting glucose or impaired glucose tolerance at the University of Missouri. The aim of the study is to advance understanding of how growth hormone affects beta-cells and risk factors for developing type 2 diabetes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 59 Years

Healthy volunteers

Yes

Inclusion criteria

* body mass index \>18.5kg/m2 and \<45.9kg/m2 * impaired fasting glucose \>/= 100mg/dL, \</= 126mg/dL or impaired glucose tolerance on 75g oral glucose tolerance test (blood glucose 140 to 199mg/dL at two-hours)

Exclusion criteria

* pregnant, planning to become pregnant during the study, or breastfeeding * current diagnosis or history of type 1 or type 2 diabetes * use of medications that can impact the study outcomes (e.g., GLP-1 receptor agonists) * history of bariatric surgery * known, uncontrolled hypothyroidism * history of intracranial hypertension, including papilledema, or a condition that increases the risk of developing intracranial hypertension, such as Turner Syndrome, Prader-Willi Syndrome, or renal impairment * current cancer or cancer that has been in remission less than 5 years * first degree relative with type 1 diabetes * evidence of anemia or significant end organ dysfunction (e.g., liver, kidney, heart disease) * alcohol use disorder, use of controlled substances, or smoking \>2 cigarettes per day * greater than 3% weight loss within three months of screening or engaged in regular (\>/= 3 days per week), continuous moderate- or high-intensity exercise of \>/= 30 min duration * mentally disabled persons, prisoners, and persons with inability to grant voluntary informed consent

Design outcomes

Primary

Measure	Time frame	Description
Beta-cell function	before and 7 days after rhGH administration	Insulin secretion rate in relationship to plasma glucose

Countries

United States

Contacts

CONTACTStudy Coordinator

ahmc4@health.missouri.edu573-884-6852

CONTACTVasavi Shabrish

v.shabrish@missouri.edu

PRINCIPAL_INVESTIGATORBettina Mittendorfer

University of Missouri-Columbia

Outcome results